| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Alprenolol (alfeprol, alpheprol) is a potent and non-selective beta blocker as well as 5-HT1A receptor antagonist, used in the treatment of angina pectoris. AstraZeneca is no longer marketing it, but generic versions or other pharmaceutical companies may still carry it.
| Targets |
5-HT1A Receptor
|
|---|---|
| ln Vitro |
Alprenolol (p.o., 50 mg/kg) results in a significant reduction in blood pressure, averaging 20 mm Hg, and an increase in heart rate, averaging 39 beats/min (at 3-hr) in conscious renal hypertensive dogs[1].
Alprenolol (i.p., 5 mg/kg) efficiently inhibits the anxiolytic effects of indorenate and ipsapirone while having no effect on motor activity the anxiolytic effects of indorenate and ipsapirone but do not reduce the motor activity in adult male Swiss Webster mice[2]. Alprenolol (intravenous injection, 0.5 or 1.0 mg/kg) can reduce heart rate by 23 beats per minute, diastolic pressure by 10 mm Hg, and systolic pressure by 10 mm Hg. It can also slightly reduce liver and myocardial blood flows by 15% and 17%, respectively at a dose of 1.0 mg/kg in cats[3]. |
| ln Vivo |
Aprapralol (oral, 50 mg/kg) significantly reduced blood pressure by an average of 20 mm Hg (3 hours) and increased heart rate by 39 beats/minute (3 hours) in conscious renally hypertensive dogs. 1]. Aprellol (intraperitoneal injection, 5 mg/kg) effectively blocks the anxiolytic effects of indomethacin and ixabepilone, but does not reduce locomotor activity in adult male Swiss Webster mice [2]. Aprapralol (intravenous injection, 0.5 or 1.0 mg/kg) can reduce systolic blood pressure by an average of 10 mm Hg and diastolic blood pressure by an average of 10 mm Hg), reduce heart rate by 23 beats/min, and slightly reduce myocardial contractility. At a dose of 1.0 mg/kg, liver blood flow in cats decreased by an average of 17% and 15% respectively [3].
|
| References |
|
| Molecular Formula |
C₁₅H₂₃NO₂
|
|---|---|
| Molecular Weight |
249.35
|
| Exact Mass |
249.17
|
| CAS # |
13655-52-2
|
| Related CAS # |
Alprenolol hydrochloride; 13707-88-5
|
| Appearance |
Powder
|
| SMILES |
CC(C)NCC(COC1=CC=CC=C1CC=C)O
|
| InChi Key |
PAZJSJFMUHDSTF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
|
| Chemical Name |
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol
|
| Synonyms |
(RS)-Alprenolol; dl-Alprenolol; Alprenolol
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~401.4 mM)
H2O: ~0.7 mg/mL (~2.7 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 4 mg/mL (16.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0104 mL | 20.0521 mL | 40.1043 mL | |
| 5 mM | 0.8021 mL | 4.0104 mL | 8.0209 mL | |
| 10 mM | 0.4010 mL | 2.0052 mL | 4.0104 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
